Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial

The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect.

Matéria Original

Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial

Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques